Evidence map›Paper›PMID 35847273›Full record

ArticleACS omega2022

Predicting the Success of Fmoc-Based Peptide Synthesis.

Ilanit Gutman, Ron Gutman, John Sidney, Leila Chihab, Michele Mishto, Juliane Liepe, Anthony Chiem, Jason Greenbaum, Zhen Yan, Alessandro Sette and 2 more

Abstract read
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ilanit GutmanCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California 92037-1387, United States.
Ron GutmanCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California 92037-1387, United States.
John SidneyCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California 92037-1387, United States.
Leila ChihabCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California 92037-1387, United States.
Michele MishtoCentre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London, London SE1 1UL, U.K.
Juliane LiepeMax-Planck-Institute for Multidisciplinary Sciences, Göttingen 37077, Germany.
Anthony ChiemTC Peptide Lab, San Diego, California 92121-4708, United States.
Jason GreenbaumBioinformatics Core Facility, La Jolla Institute for Immunology, La Jolla, California 92037-1387, United States.ORCID https://orcid.org/0000-0002-1381-0390
Zhen YanBioinformatics Core Facility, La Jolla Institute for Immunology, La Jolla, California 92037-1387, United States.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California 92037-1387, United States.
Zeynep Koşaloğlu-YalçınCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California 92037-1387, United States.ORCID https://orcid.org/0000-0003-0961-5055
Bjoern PetersCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California 92037-1387, United States.

Funding

IMMUNE EPITOPE AND ANALYSIS PROGRAM: Transplantation of organs, tissues and cells 75N93019C00001 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI WILSON, STEPHEN · 2019 to 2025
$23.1M
THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCEU24CA248138 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI PETERS, BJOERN, SETTE, ALESSANDRO · 2021 to 2025
$4.6M
Cancer Research UK 29686NCI NIH HHS U24 CA248138NIAID NIH HHS 75N93019C00001
6 · The paper itself

Abstract

Synthetic peptides are commonly used in biomedical science for many applications in basic and translational research. While peptide synthesis is generally easy and reliable, the chemical nature of some amino acids as well as the many steps and chemical compounds involved can render the synthesis of some peptide sequences difficult. Identification of these problematic sequences and mitigation of issues they may present can be important for the reliable use of peptide reagents in several contexts. Here, we assembled a large dataset of peptides that were synthesized using standard Fmoc chemistry and whose identity was validated using mass spectrometry. We analyzed the mass spectra to identify errors in peptide syntheses and sought to develop a computational tool to predict the likelihood that any given peptide sequence would be synthesized accurately. Our model, named Peptide Synthesis Score (PepSySco), is able to predict the likelihood that a peptide will be successfully synthesized based on its amino acid sequence.

Identifiers

PMID35847273
PMCPMC9280948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.